NVST or ABT: Which Is the Better Value Stock Right Now?

Core Viewpoint - Investors in the Medical - Products sector should consider Envista (NVST) and Abbott (ABT) for potential value opportunities, with NVST currently presenting a more attractive option based on various valuation metrics and earnings outlook [1][3][7]. Valuation Metrics - NVST has a forward P/E ratio of 18.81, while ABT has a higher forward P/E of 24.16, indicating that NVST may be undervalued compared to ABT [5]. - The PEG ratio for NVST is 1.23, suggesting a better valuation relative to its expected earnings growth compared to ABT's PEG ratio of 2.36 [5]. - NVST's P/B ratio stands at 1.09, significantly lower than ABT's P/B ratio of 4.41, further indicating NVST's relative undervaluation [6]. Earnings Estimate Revisions - NVST has experienced stronger estimate revision activity, which is a positive indicator for its earnings outlook compared to ABT [3][7]. - The Zacks Rank system rates NVST as 2 (Buy) and ABT as 3 (Hold), reflecting a more favorable earnings estimate revision trend for NVST [3]. Value Grades - NVST has been assigned a Value grade of B, while ABT has a Value grade of C, highlighting NVST's superior valuation metrics [6].